Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence

Use of Letermovir as Salvage Therapy for Drug-resistant CMV Retinitis: A Case Series

(2019) Nicholas Turner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A prospective multicenter observational study of cell‐mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients

(2019) Deepali Kumar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis

(2019) Ajit P Limaye et al.   JOURNAL OF INFECTIOUS DISEASES

New vaccines and antiviral drugs for cytomegalovirus

(2019) Paul Griffiths   JOURNAL OF CLINICAL VIROLOGY

A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor

(2018) Flavio Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients

(2018) Smaranda Gliga et al.   JOURNAL OF CLINICAL VIROLOGY

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

(2018) Camille N. Kotton et al.   TRANSPLANTATION

Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation

(2018) Nicolle H. R. Litjens et al.   Frontiers in Immunology

Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection

(2018) Lauren Cherrier et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

(2018) Genovefa A Papanicolaou et al.   CLINICAL INFECTIOUS DISEASES

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

(2018) Francisco M. Marty et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Virus-Specific T Cells for the Immunocompromised Patient

(2017) Amy Houghtelin et al.   Frontiers in Immunology

Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung Transplantation

(2016) Laurie D. Snyder et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

(2016) P. Teira et al.   BLOOD

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients

(2016) F. El Chaer et al.   BLOOD

Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis

(2016) E. Beam et al.   CLINICAL TRANSPLANTATION

Characteristics and outcomes of neutropenia after orthotopic liver transplantation

(2016) Basem Alraddadi et al.   LIVER TRANSPLANTATION

Cytomegalovirus Immunoglobulin After Thoracic Transplantation

(2016) Paolo Grossi et al.   TRANSPLANTATION

Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection

(2016) Robin K. Avery et al.   TRANSPLANTATION

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial

(2016) Ryotaro Nakamura et al.   Lancet Haematology

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

(2016) Margaret L Green et al.   Lancet Haematology

Valganciclovir for the Prevention of Complications of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation

(2015) Michael Boeckh et al.   ANNALS OF INTERNAL MEDICINE

RapidIn VitroEvolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance

(2015) Sunwen Chou   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis

(2015) D.R. Stevens et al.   Transplant Infectious Disease

CMV Prophylaxis in Hematopoietic-Cell Transplantation

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Transient residence of a seropositive organ is sufficient to transfer human cytomegalovirus to a seronegative recipient

(2014) H.A. Lumgair et al.   Transplant Infectious Disease

Cytomegalovirus in Solid Organ Transplantation

(2013) R. R. Razonable et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation

(2013) Scott M. Palmer   ANNALS OF INTERNAL MEDICINE

Quantitation of Cytomegalovirus DNA Load in Dried Blood Spots Correlates Well with Plasma Viral Load

(2013) A. P. Limaye et al.   JOURNAL OF CLINICAL MICROBIOLOGY

CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

(2013) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

(2012) Mohamed A Kharfan-Dabaja et al.   LANCET INFECTIOUS DISEASES

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis

(2012) A.P. Wiita et al.   Transplant Infectious Disease

Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients

(2011) A. H. Elmaagacli et al.   BLOOD

Primary Cytomegalovirus Phosphoprotein 65–Specific CD8+ T-Cell Responses and T-bet Levels Predict Immune Control During Early Chronic Infection in Lung Transplant Recipients

(2011) Matthew R. Pipeling et al.   JOURNAL OF INFECTIOUS DISEASES

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

(2011) Paul D Griffiths et al.   LANCET

Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial

(2011) Oliver Witzke et al.   TRANSPLANTATION

Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

(2010) Atul Humar et al.   TRANSPLANTATION

Adoptive T-Cell Therapy of a Lung Transplanted Patient with Severe CMV Disease and Resistance to Antiviral Therapy

(2009) G. Brestrich et al.   AMERICAN JOURNAL OF TRANSPLANTATION

How we treat cytomegalovirus in hematopoietic cell transplant recipients

(2009) M. Boeckh et al.   BLOOD

An Assessment of Donor‐to‐Recipient Transmission Patterns of Human Cytomegalovirus by Analysis of Viral Genomic Variants

(2009) Oriol Manuel et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of Posttransplant Cytomegalovirus Disease and Related Outcomes with Valganciclovir: A Systematic Review

(2008) H-Y. Sun et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial

(2008) V. Kliem et al.   AMERICAN JOURNAL OF TRANSPLANTATION